|
Post by robsacher on Nov 30, 2015 18:17:21 GMT -5
This thread is about depressing as it gets. Unfortunately, we have no information going forward. Will MNKD get bought? Will it Bankrupt? Will Al take it private? Who knows. We are in the dark. At $2/share, it makes no sense to sell. Most of us have already lost quite a bit on this investment. So where do we go from here? I, for one, am holding on. I know the product is great. I know Technosphere has amazing potential. I know SOMETHING will work out. I am adding to my position.
|
|
|
Post by irrationalexubera on Nov 30, 2015 19:37:12 GMT -5
^^^ same here.
|
|
|
Post by doublebogey on Nov 30, 2015 19:56:40 GMT -5
Same here. I'm also adding to my position.
|
|
|
Post by mnholdem on Nov 30, 2015 20:21:32 GMT -5
If Sanofi has also been waiting for results from the post-marketing trials related to dosing, they now have the data. The FDA site has just been updated during the past few days and the 2nd trial study is now complete.
The FDA does state on its website that certain results could lead to a label change. I imagine Sanofi, MannKind and the FDA will be meeting to discuss the findings. If you are a believer in the pilot program theory, then an FDA decision could be the final news that Sanofi was waiting for, IMHO.
|
|
|
Post by suebeeee1 on Nov 30, 2015 22:11:20 GMT -5
I blew my pocket change when I doubled my position last mont at $1.76 during the TASE FUD fiasco.
But, I've got to believe something is in the works. You can almost feel it in the air!
|
|
|
Post by compound26 on Dec 1, 2015 0:37:34 GMT -5
I have posted the following in anther post. But since it also appears relevant to this post. I am also posting the following here:
Interestingly, here is one of the members in Linked-in, her profile is as follows:
LinkedIn Member
Sales Manager / Business Leader / Consultative Sales / Business Development / Strategic Planning / Account Management
Columbia, South Carolina AreaPharmaceuticals
Senior Diabetes Sales Professional at Sanofi
...as one of a select group of reps to pilot launch of Afrezza, an inhaled insulin product; achieved...
|
|
|
Post by rch51 on Dec 1, 2015 0:48:20 GMT -5
I have posted the following in anther post. But since it also appears relevant to this post. I am also posting the following here: Interestingly, here is one of the members in Linked-in, her profile is as follows: LinkedIn Member Sales Manager / Business Leader / Consultative Sales / Business Development / Strategic Planning / Account Management Columbia, South Carolina AreaPharmaceuticals Senior Diabetes Sales Professional at Sanofi ... as one of a select group of reps to pilot launch of Afrezza, an inhaled insulin product; achieved... Hmmm.... Now THAT is interesting
|
|
|
Post by fedakd on Dec 1, 2015 1:35:18 GMT -5
Shareholders likely have a case for a class action if this is true. I'm a long, but if they have only "piloted" Afrezza while also saying they're unhappy with scripts, that is grounds for class action.
|
|
|
Post by EveningOfTheDay on Dec 1, 2015 13:31:05 GMT -5
Shareholders likely have a case for a class action if this is true. I'm a long, but if they have only "piloted" Afrezza while also saying they're unhappy with scripts, that is grounds for class action. Well, they have not been as specific as to say they are unhappy, have they? At least that I remember. They have said scripts are under estimations for the time but that it is still early to fully assess the situation. Actually, last time we hear about the situation was to tell us they were 8 weeks behind estimates and that was quite a while ago, we have not been informed on how behind estimates we are anymore, probably because the company considers it too much of a reality check to let us know. I think zebras... forget zebras, I think unicorns and I can come up, after much juggling and some literary liberties, with a way to line up everything that has transpired over the last year to support the idea of a piloted launch. However, at this point, it is a card castle on top of a flimsy sheet of cardboard that I am balancing on one finger at best. The slightest thing will bring it down quickly, so...
|
|
|
Post by bradleysbest on Dec 1, 2015 13:40:25 GMT -5
Add each week since that statement was made and bingo that is how many weeks we are behind! Relax just having some fun...
|
|
|
Post by jeremg on Dec 1, 2015 13:41:38 GMT -5
Shareholders likely have a case for a class action if this is true. I'm a long, but if they have only "piloted" Afrezza while also saying they're unhappy with scripts, that is grounds for class action. Well, they have not been as specific as to say they are unhappy, have they? At least that I remember. They have said scripts are under estimations for the time but that it is still early to fully assess the situation. Actually, last time we hear about the situation was to tell us they were 8 weeks behind estimates and that was quite a while ago, we have not been informed on how behind estimates we are anymore, probably because the company considers it too much of a reality check to let us know. I think zebras... forget zebras, I think unicorns and I can come up, after much juggling and some literary liberties, with a way to line up everything that has transpired over the last year to support the idea of a piloted launch. However, at this point, it is a card castle on top of a flimsy sheet of cardboard that I am balancing on one finger at best. The slightest thing will bring it down quickly, so... Considering scripts have barely moved since they said this, I can only assume we are now 8wks + as many weeks as it's been since we heard this - behind estimates. EOTD I think you are one of the few posters left who does not think zebras; unicorns on the other hand, some have seemingly progressed to unicorns per the latest "pilot" theory du jour.
|
|
|
Post by jeremg on Dec 1, 2015 13:42:23 GMT -5
Add each week since that statement was made and bingo that is how many weeks we are behind! Relax just having some fun... You beat me to it with your punchline.
|
|
|
Post by bradleysbest on Dec 1, 2015 13:43:24 GMT -5
We need some chuckles every now & then... Only way I can keep sane!
|
|
|
Post by mnkdnut on Dec 1, 2015 13:45:12 GMT -5
If it's truly a "Pilot" launch, that means to me it's an evaluation of set duration (eg. one year) and number of doctors. After that duration, SNY evaluates the results including collecting feedback from the prescribing docs. In that case, the doctors already know they're part of a Pilot. Those of you that are patients or know patients, can try asking their doctor/prescriber to confirm their participation in it. Typically, in a Pilot evaluation, the company won't comment on progress until after it's all done (SNY has already commented on disappointing sales so far). It's more likely a controlled or limited launch, where the doctors aren't aware of anything other than the product has been launched.
|
|
|
Post by mssciguy on Dec 1, 2015 13:46:41 GMT -5
Well, they have not been as specific as to say they are unhappy, have they? At least that I remember. They have said scripts are under estimations for the time but that it is still early to fully assess the situation. Actually, last time we hear about the situation was to tell us they were 8 weeks behind estimates and that was quite a while ago, we have not been informed on how behind estimates we are anymore, probably because the company considers it too much of a reality check to let us know. I think zebras... forget zebras, I think unicorns and I can come up, after much juggling and some literary liberties, with a way to line up everything that has transpired over the last year to support the idea of a piloted launch. However, at this point, it is a card castle on top of a flimsy sheet of cardboard that I am balancing on one finger at best. The slightest thing will bring it down quickly, so... Considering scripts have barely moved since they said this, I can only assume we are now 8wks + as many weeks as it's been since we heard this - behind estimates. EOTD I think you are one of the few posters left who does not think zebras; unicorns on the other hand, some have seemingly progressed to unicorns per the latest "pilot" theory du jour. nRx tRx may have flatlined but refills prntscr.com/996ldk ... show a linear rise. IMS, Symphony agree well in this area, the other numbers may be very noisy. Now that the word on COSTCO is out, that alone may bump up the numbers.
|
|